Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells

Molecular Cancer Therapeutics

Volumn 9, Issue 1, 2010, Pages 33-45

  Mishra, Dhruva Kumar ^a   Chen, Zujian ^a   Wu, Yanyuan ^a,b   Sarkissyan, Marianna ^a   Koeffler, H Phillip ^b,c   Vadgama, Jaydutt V ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PYROXYLIN;

ARTICLE; CANCER CELL CULTURE; CASP8 GENE; CD14 GENE; CDKN2A GENE; CHEMOLUMINESCENCE; CIITA GENE; CONTROLLED STUDY; CPG ISLAND; DAPK GENE; DIAGNOSTIC KIT; DNA METHYLATION; EPIGENETICS; FHIT GENE; GAGE1 GENE; GATA3 GENE; GENE; GPC3 GENE; HUMAN; HUMAN CELL; IFN GENE; IGRP GENE; MALE; MDR1 GENE; MGMT GENE; MLC1 GENE; MYOD GENE; NPAT GENE; P27KIP1 GENE; PAX6 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RB GENE; RBL1 GENE; RIOK3 GENE; SRBC GENE; STAT1 GENE; STAT5 GENE; TMS1 GENE; TUMOR SUPPRESSOR GENE;

ANDROGENS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RNA, MESSENGER; TAXOIDS;

EID: 73949121977     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0486     Document Type: Article

References (29)

1. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349: 2042-54.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21: 5427-40.
5. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
6. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
7. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-9.
8. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79: 1370-80.
9. Enokida H, Shiina H, Urakami S, et al. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer 2006;106:79-86.
10. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res 1980;8:4777-90.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
12. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
13. Jeronimo C, Henrique R, Oliveira J, et al. Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J Clin Pathol 2004;57:872-6.
14. Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10: 8472-8.
15. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004;202:233-40.
16. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9.
17. Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106:382-7.
18. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000;60:6236-42.
19. Das PM, Ramachandran K, Vanwert J, et al. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer 2006; 5:28.
20. Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB. Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate 2001;48:248-53.
21. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada K. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 2002;160:1207-14.
22. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.
23. Lee H, Yu H. Methylation of Stat1 promoter can contribute to squamous cell carcinogenesis. J Natl Cancer Inst 2006;98:154-5.
24. Hiranuma C, Kawakami K, Oyama K, Ota N, Omura K, Watanabe G. Hypermethylation of the MYOD1 gene is a novel prognostic factor in patients with colorectal cancer. Int J Mol Med 2004;13:413-7.
25. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006;27:405-12.
26. Enokida H, Shiina H, Urakami S, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005; 11:6582-8.
27. Wang Y, Yu Q, Cho AH, et al. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 2005;7: 748-60.
28. Yamada Y, Toyota M, Hirokawa Y, et al. Identification of differentially methylated CpG islands in prostate cancer. Int J Cancer 2004;112: 840-5.
29. Yu YP, Paranjpe S, Nelson J, et al. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 2005;26:471-9.